Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Radient Selling its China Subsidiary, Jade Pharma

publication date: Apr 14, 2010
Radient Pharmaceuticals currently expects prospective purchasers of its China subsidiary, Jade Pharmaceutical, Inc. to complete their due diligence by the end of May 2010. Radient, which announced plans to divest itself of Jade in Q3 of 2009, places a $20 million value on Jade. It owns 98% of the China enterprise, though Radient doesn’t expect to realize nearly that much upon the sale. More details...

Stock Symbol: (NYSE Amex: RPC)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital